Non Interventional Study Dealing With the Use of Trabectedin (Yondelis)-Pegylated Liposomal Doxorubicin (Caelyx) in Patient With Platinum-sensitive Relapse

Next Previous
Trial Profile

Non Interventional Study Dealing With the Use of Trabectedin (Yondelis)-Pegylated Liposomal Doxorubicin (Caelyx) in Patient With Platinum-sensitive Relapse

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Trabectedin (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Acronyms PROSPECTYON

    • Most Recent Events

    • 12 Sep 2017 Results (n=91; as of Jun 2016) presented at the 42nd European Society for Medical Oncology Congress
    • 23 Aug 2017 Planned End Date changed from 1 Jan 2017 to 1 Dec 2017.
    • 15 Jun 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top